# HS-20093 in Patients with Advanced Esophageal Carcinoma and Other Advanced Solid Tumors

Source: https://onco.cc/trials/nct06112704/  
OnCo record `nct06112704` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of HS-20093 in advanced solid tumours, run by Hansoh BioMedical R&D Company, now recruiting.

## Summary

HS-20093 in Patients with Advanced Esophageal Carcinoma and Other Advanced Solid Tumors is a phase 2 interventional study registered as NCT06112704 by Hansoh BioMedical R&D Company, with 220 participants planned, started 2024-02-06 and due to reach its primary completion in 2026-07-31. Interventions recorded: HS-20093.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06112704
- Phase: 2
- Setting: A Phase 2, Open-label, Multi-center Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Immunogenicity of HS-20093 in Patients with Advanced Esophageal Carcinoma and Other Advanced Solid Tumors (ARTEMIS-005)
- Sponsor: Hansoh BioMedical R&D Company
- Enrolled: 220

## Sources

- ClinicalTrials.gov NCT06112704: https://clinicaltrials.gov/study/NCT06112704

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [HS-20093](https://onco.cc/drugs/hs-20093/)

---
JSON: https://onco.cc/api/v1/entities/nct06112704.json